ACUTE RHINOSINUSITIS : NASONEX AS ADJUNCTIVE THERAPY

Authors

Mahmoud A Yosef, "Assistant Professor of Otorhinolaryngology, Faculty of Medicine, Mansoura University
Sameh M. Hakim, Lecturer of Anesthesiology, Faculty of Medicine, Ain Shams University

Article Type

Original Study

Abstract

This study evaluates the effec­tiveness and safety of mometascne furoate nasal spray (MFNS; Nason-ex®, Schering, Kenilworth, NJ) as adjunctive treatment with oral antibio­tic; amoxicillin/clavulanate potassium (ACP; Augmentin®, GlaxoSmithKline, Research Triangle Park, NC) for acute rhinosinusitis. In a double-blind, placebo-controlled study, 75 outpa­tients with moderate to severe rhin­osinusitis received ACP, 875 mg, twice daily, for 21 days with adjunc­tive twice daily MFNS 200 ng, MFNS 400 fig, or placebo nasal spray. MFNS significantly improves the symptoms of rhinosinusitis. Both doses of MFNS were well tolerated without significant treatment-related adverse events.

Recommended Citation

Yosef, Mahmoud A and Hakim, Sameh M. (2003) "ACUTE RHINOSINUSITIS : NASONEX AS ADJUNCTIVE THERAPY," Mansoura Medical Journal: Vol. 32 : Iss. 2 , Article 4.
Available at: https://doi.org/10.21608/mjmu.2003.127239

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.